Insulin Market Size, Share, Growth, and Industry Analysis, By Type (Animal Insulin, Regular Human Insulin, Insulin Analogue), By Application (Rapid Acting, Short Acting, Intermediate Acting, Long Acting, Pre-Mix Insulin), Regional Insights and Forecast to 2035

Insulin Market Overview

The global insulin market is likely to grow from USD 18854.47 million in 2026 to USD 21120.78 million in 2035, with an average CAGR of 1.27% during the forecast period.

The insulin market in 2026 is being shaped by increasing diabetes prevalence, widening diagnosis, greater use of insulin analogues, biosimilar competition, advanced delivery devices and the emergence of once-weekly basal formulations. Around 830 million people were living with diabetes globally in 2022, compared with approximately 200 million in 1990, while adult diabetes prevalence increased from 14% over the same period. These figures demonstrate a substantial long-term requirement for effective glucose-lowering treatment. Insulin Analogue continues to account for the largest proportion of insulin demand because modified pharmacokinetic profiles provide convenient basal and mealtime management, while Regular Human Insulin remains essential across affordability-focused healthcare environments. Product innovation is increasingly focused on reducing treatment burden, and once-weekly basal insulin has moved into commercial use during 2026. Such products reduce basal administration from 7 injections per week to 1, representing an important shift in long-term type 2 diabetes management. Biosimilar insulin development is simultaneously increasing competition in Rapid Acting and Long Acting categories.

The United States remains one of the most developed insulin markets, supported by approximately 38 million adults living with diabetes, extensive endocrinology infrastructure, widespread insulin-pen adoption and high utilization of continuous glucose monitoring. The market entered an important technological phase in 2026 with regulatory approval of once-weekly basal insulin options. The first once-weekly basal insulin for adults with type 2 diabetes received U.S. approval in March 2026, followed by another weekly basal formulation in September 2026. These products can reduce conventional daily basal administration from approximately 365 injections annually to around 52. Biosimilar competition is also expanding. The first U.S. rapid-acting insulin biosimilar was approved in February 2025 and was made available through a 3 mL prefilled pen and a 10 mL multidose vial. These developments are encouraging manufacturers to differentiate through dosing convenience, administration technology, product availability, manufacturing scale and patient-support capabilities.

Download FREE Sample to learn more about this report.

Key Findings

• Leading Product Type: Insulin Analogue is expected to lead the market with an estimated 69.8% share during 2026, supported by broader adoption of advanced basal, mealtime and extended-duration formulations across developed diabetes-care systems.
• Leading Application: Long Acting insulin is projected to represent approximately 44.7% of application demand in 2026 as basal glucose management remains fundamental for millions of patients requiring sustained insulin coverage throughout the day.
• Leading Region: North America is estimated to account for approximately 39.6% of insulin demand in 2026, supported by high treatment penetration, established reimbursement, advanced delivery technology and early adoption of new insulin formulations.
• Fastest Growing Region: Asia-Pacific is expected to record the strongest volume expansion, supported by adult diabetes prevalence approaching 20% in parts of the wider regional disease environment and continued expansion of treatment infrastructure.
• Technology Trend: Once-weekly basal insulin is transforming treatment convenience by reducing basal administration from 7 injections every week to 1, creating an important innovation pathway focused on persistence, adherence and simplified diabetes management.
• Market Driver: Diabetes prevalence remains the primary demand driver, with approximately 830 million people living with diabetes worldwide in 2022 compared with nearly 200 million individuals in 1990.
• Competitive Landscape: Competitive intensity is rising through biosimilar development and long-duration innovation, with the first U.S. rapid-acting insulin biosimilar receiving approval in February 2025 across 2 delivery presentations.
• Future Outlook: Future insulin strategies will increasingly prioritize treatment access as global diabetes objectives target affordable insulin and blood-glucose self-monitoring access for 100% of people living with type 1 diabetes by 2030.

Latest Trends

The strongest technology trend affecting the insulin market is the movement from conventional daily basal treatment toward once-weekly administration. Daily basal insulin usually requires approximately 7 injections per week and about 365 injections each year, while weekly formulations can reduce the requirement to around 52 injections annually. In March 2026, the first once-weekly basal insulin received U.S. approval for adults with type 2 diabetes, establishing a new treatment category centered on convenience and reduced administration burden. A second once-weekly basal insulin received U.S. approval in September 2026 following a Phase 3 clinical program involving more than 3,400 adults with type 2 diabetes. These developments indicate that product differentiation is moving beyond conventional duration categories toward therapies designed to simplify long-term treatment routines. Manufacturers are increasing research around prolonged molecular activity, high-concentration formulations, stable pharmacokinetics and simplified titration. The shift is particularly relevant for patients who delay insulin initiation because of daily injection concerns or difficulty maintaining consistent treatment schedules.

Biosimilar insulin and digitally supported administration represent another important market trend. The U.S. regulatory environment approved its first rapid-acting insulin biosimilar in February 2025, widening competition beyond established long-acting biosimilars. The product entered the market through 2 delivery formats consisting of a 3 mL prefilled pen and a 10 mL multidose vial, demonstrating how biosimilar competition is increasingly extending into convenient administration systems. Insulin treatment is also becoming more closely connected with continuous glucose monitoring, connected pens and mobile dose-management platforms. These technologies enable patients to review glucose behavior alongside insulin administration and can support more informed treatment adjustment. The combination of biosimilar competition and digital diabetes management is creating a dual market structure. Premium innovation is focused on longer duration and greater convenience, while cost-sensitive competition is centered on manufacturing efficiency, reliable supply and broader patient access. This environment supports continued relevance for both Insulin Analogue and Regular Human Insulin throughout the forecast period.

Market Dynamics

Driver

""Expanding diabetes prevalence continues to strengthen long-term insulin demand.""

The largest structural driver for the insulin market is the continuous expansion of the global diabetes population. Approximately 830 million people were living with diabetes in 2022 compared with about 200 million in 1990, representing more than a 4-fold increase. Adult diabetes prevalence increased from approximately 14% during the same period, demonstrating that healthcare systems are managing a rapidly growing chronic-disease burden. Insulin remains essential for people living with type 1 diabetes and becomes necessary for many individuals with type 2 diabetes as pancreatic beta-cell function declines. The growing number of diagnosed patients therefore creates recurring long-term demand rather than short-duration treatment demand. Improved survival among people with diabetes further increases treatment duration, meaning many insulin users remain on therapy for decades. National screening programs and greater primary-care awareness are also identifying more patients at earlier stages. International diabetes targets call for approximately 80% of people with diabetes to be diagnosed by 2030, potentially expanding the treated population and strengthening demand for multiple insulin categories.

The clinical importance of glycemic control provides an additional demand foundation. Diabetes and diabetes-related kidney disease caused more than 2 million deaths globally in 2021, while elevated blood glucose contributes to cardiovascular complications, neurological damage, vision impairment and kidney dysfunction. Effective glucose management therefore remains a major healthcare priority. Insulin manufacturers address this requirement through 5 supplied application categories comprising Rapid Acting, Short Acting, Intermediate Acting, Long Acting and Pre-Mix Insulin. These formulations support different treatment schedules, from mealtime glucose control to sustained basal therapy. Long Acting insulin is particularly important for patients requiring background glucose management throughout a 24-hour period, while Rapid Acting insulin supports meal-related dosing. The availability of multiple pharmacokinetic profiles allows physicians to adjust treatment according to individual needs. As the diagnosed diabetes population increases and treatment protocols become more personalized, demand for differentiated insulin formulations is expected to remain resilient through 2035 despite the increasing availability of non-insulin diabetes medicines.

Restraint

""Treatment gaps and affordability continue to restrict wider insulin accessibility.""

Insulin access remains uneven despite the large global diabetes population. Around 59% of adults aged 30 years and older living with diabetes were not taking medication for their condition in 2022, representing approximately 450 million untreated adults. About 90% of those untreated individuals were living in low- and middle-income countries. This gap illustrates that rising prevalence does not automatically translate into proportional insulin utilization. Insulin therapy requires reliable medicine availability, trained healthcare professionals, appropriate storage, glucose-monitoring equipment and ongoing clinical follow-up. These requirements create significant barriers in rural and resource-limited environments where cold-chain systems and specialist diabetes services may be insufficient. Advanced Insulin Analogue products can also be more difficult to access where reimbursement coverage is limited. Regular Human Insulin therefore continues to play an important role in affordability-focused markets, but even established formulations may remain inaccessible to patients without reliable public procurement or insurance coverage. Improving treatment availability remains essential for converting unmet clinical need into effective insulin use.

The availability of alternative type 2 diabetes medicines also moderates the speed of insulin initiation in some patient groups. Modern diabetes care increasingly uses several pharmacological approaches before moving patients to injectable insulin, particularly when satisfactory glucose control can be maintained using other treatments. This creates a restraint for insulin volume growth among adults in earlier stages of type 2 diabetes. Manufacturers are responding by simplifying administration and reducing treatment burden. Once-weekly basal insulin, for example, reduces the frequency of administration from 7 injections each week to 1 and can therefore address concerns associated with daily injections. However, adoption remains dependent on physician confidence, reimbursement decisions, patient suitability and long-term treatment experience. Healthcare systems also evaluate whether newer formulations provide sufficient practical benefits to justify changes from established daily insulin. As a result, insulin companies must increasingly demonstrate convenience, adherence benefits and dependable glycemic control while maintaining competitive pricing in a treatment environment containing a growing number of non-insulin options.

Opportunity

""Once-weekly therapy creates a major opportunity to reduce treatment burden.""

Longer-duration insulin is creating a significant opportunity for manufacturers to improve treatment convenience and strengthen patient persistence. Once-weekly basal formulations can reduce a patient's administration burden from approximately 365 injections annually to about 52. This represents more than 300 fewer injections each year compared with once-daily basal treatment. The category moved into a new commercial phase in 2026 when multiple weekly basal products obtained regulatory approval in the United States. One major once-weekly insulin development program evaluated more than 3,400 adults with type 2 diabetes, demonstrating the scale of clinical investment supporting the technology. Weekly administration may be particularly attractive for patients reluctant to initiate insulin because of injection frequency, travel requirements or complex daily routines. Manufacturers can further differentiate these products through prefilled devices, simplified titration guidance and digital dose reminders. As diabetes management becomes increasingly patient-centered, reducing treatment burden while maintaining predictable glucose control is likely to become an increasingly important competitive advantage.

Emerging economies provide another substantial market opportunity because diabetes prevalence is growing rapidly while treatment coverage remains comparatively low. Adult diabetes prevalence has approached approximately 20% in parts of the South-East Asia and Eastern Mediterranean disease environment, yet treatment coverage remains considerably lower than in many developed healthcare systems. Asia-Pacific is particularly important because expanding insurance coverage, urban healthcare infrastructure, pharmacy networks and domestic biologics manufacturing are increasing insulin availability. Chinese manufacturers including Tonghua Dongbao, Ganlee, United Laboratory and Jiangsu Wanbang strengthen regional competition and support localized production. Regular Human Insulin remains important where affordability influences treatment decisions, while Insulin Analogue adoption is expected to increase as healthcare spending and reimbursement improve. Global diabetes objectives targeting affordable insulin access for 100% of people with type 1 diabetes by 2030 may further encourage manufacturing investment, procurement reform and distribution expansion. Companies capable of combining scalable production with broad geographic coverage are positioned to benefit from this large untreated and undertreated patient population.

Challenge

""Biologic manufacturing complexity increases pressure on global insulin suppliers.""

Insulin manufacturing remains technically demanding because commercial production requires controlled biological processing, purification, formulation, sterile filling and detailed quality validation. Production facilities must maintain consistent potency and purity across millions of doses because small variations can influence treatment performance. Modern insulin manufacturers also need specialized cartridge, vial and prefilled-pen assembly capabilities alongside temperature-controlled distribution networks. These requirements become increasingly complex as portfolios expand beyond established Regular Human Insulin toward advanced analogues and weekly formulations. Once-weekly insulin requires pharmacokinetic performance across 7 days, placing higher technical demands on molecular design and formulation stability. Manufacturers therefore need substantial investment in research, biologics processing, analytical testing and regulatory compliance. Supply interruptions can also have significant consequences because insulin users require continuous treatment rather than occasional therapy. Maintaining redundant production capacity and regional distribution infrastructure is becoming strategically important as diabetes populations expand across multiple geographies.

Competitive intensity creates another major challenge. Biosimilar products are entering established insulin categories while multinational manufacturers are simultaneously introducing longer-duration formulations. The first rapid-acting insulin biosimilar approved in the United States in February 2025 joined 2 previously approved long-acting insulin biosimilars, increasing competitive pressure across both basal and mealtime therapy. Manufacturers can no longer rely exclusively on product familiarity and must differentiate through dosing convenience, device usability, manufacturing reliability and patient support. Weekly basal insulin raises the innovation benchmark further because it reduces administration from approximately 7 injections each week to 1. At the same time, healthcare systems continue to demand affordable treatment for growing diabetes populations. Companies must therefore balance investment in advanced products with the need to manufacture established formulations efficiently. Managing these 2 priorities simultaneously is likely to remain one of the industry's most important strategic challenges through 2035.

Download FREE Sample to learn more about this report.

Segmentation Analysis

The insulin market is segmented across 3 supplied product types and 5 supplied applications, reflecting significant differences in formulation design, pharmacokinetics and treatment requirements. Insulin Analogue is estimated to represent approximately 69.8% of product demand in 2026, while Long Acting insulin accounts for approximately 44.7% of application demand. The segmentation structure demonstrates how the market has increasingly shifted toward products offering more predictable glucose control and longer duration while retaining established options for affordability-focused treatment programs.

By Types

Animal Insulin: Animal Insulin is estimated to account for approximately 3.7% of the product-type market in 2026. Its position has declined substantially as recombinant Regular Human Insulin and engineered Insulin Analogue formulations have become the standard across most modern healthcare systems. Animal-derived products nevertheless retain limited relevance among selected long-term users and specialized clinical situations. Manufacturing investment has increasingly moved toward recombinant technologies because they enable standardized production, scalable capacity and compatibility with modern injection devices. Animal Insulin therefore represents a niche category compared with the other 2 supplied product types. Through 2035, its share is expected to remain comparatively small as newly diagnosed patients increasingly begin therapy with human recombinant or analogue formulations. However, continued patient preference and individual treatment response are expected to preserve a limited commercial requirement.

Regular Human Insulin: Regular Human Insulin is estimated to represent approximately 26.5% of product demand in 2026. It remains important across government procurement programs, hospitals and cost-sensitive treatment environments because of its established clinical profile and mature manufacturing technology. Decades of use have created considerable physician familiarity, and recombinant production enables manufacturers to supply large patient populations. Regular Human Insulin is especially relevant in markets where advanced analogues are not universally reimbursed or where patients face high out-of-pocket expenditure. Approximately 450 million adults with diabetes remained untreated in 2022, demonstrating the importance of accessible treatment options as governments attempt to improve coverage. Although Insulin Analogue is gradually increasing its share, Regular Human Insulin is expected to retain a substantial position through 2035 because affordability, established treatment protocols and public-sector purchasing continue to support demand.

Insulin Analogue: Insulin Analogue is expected to account for approximately 69.8% of product demand in 2026, making it the largest supplied category. Analogue formulations are engineered to provide modified absorption profiles that can support faster mealtime activity or longer basal coverage compared with traditional insulin. This flexibility has made them central to modern diabetes management across North America, Europe and increasingly Asia-Pacific. Innovation within the category now extends from daily basal and rapid-acting products toward once-weekly formulations capable of maintaining basal activity for 7 days. Biosimilar analogue development is also expanding, creating greater competition while potentially improving patient access. The category benefits from strong physician adoption, extensive pen-based administration and compatibility with continuous glucose-monitoring strategies. Through 2035, Insulin Analogue is expected to remain the principal area for product innovation, biosimilar development and investment in advanced delivery technologies.

By Applications

Rapid Acting: Rapid Acting insulin is estimated to account for approximately 24.1% of application demand in 2026. These formulations are widely used to control meal-related glucose elevations and remain important for intensive insulin-management regimens. Their market position is being influenced by growing biosimilar competition, particularly after the first U.S. rapid-acting insulin biosimilar received approval in February 2025. The product was authorized through both a 3 mL prefilled pen and a 10 mL multidose vial, demonstrating the increasing importance of administration convenience within the category. Continuous glucose monitoring is also strengthening the role of Rapid Acting insulin because patients can observe post-meal glucose behavior more closely. The category is expected to remain strategically important through 2035, particularly for people with type 1 diabetes and adults using structured basal-bolus therapy.

Short Acting: Short Acting insulin is estimated to represent approximately 11.6% of application demand in 2026. The category maintains an established role in diabetes treatment and remains particularly important in healthcare environments where Regular Human Insulin is widely used. Short Acting insulin benefits from decades of clinical experience, familiar dosing protocols and comparatively mature manufacturing economics. Its share has gradually declined in higher-income markets as Rapid Acting analogue products have become more common because of their faster pharmacokinetic profiles. Nevertheless, Short Acting insulin retains significant importance for affordability-focused patients, public procurement programs and healthcare systems where analogue penetration remains limited. With approximately 830 million people living with diabetes globally, even a moderate application share represents a substantial patient population requiring reliable product availability and consistent supply.

Intermediate Acting: Intermediate Acting insulin is estimated to hold approximately 8.4% of application demand in 2026. These formulations historically provided an important basal treatment option before longer-duration analogue products became widely available. Intermediate Acting insulin remains relevant across traditional treatment regimens and affordability-sensitive settings where established protocols continue to be used. However, its market position faces pressure from Long Acting insulin products offering more prolonged and predictable basal activity. The emergence of once-weekly basal technology further increases competitive pressure because newer products can provide coverage across 7 days from a single administration. Even so, Intermediate Acting insulin is expected to remain available through 2035 because of physician familiarity, established procurement programs and continued use in markets where advanced analogues are less accessible.

Long Acting: Long Acting insulin is estimated to account for approximately 44.7% of application demand in 2026, making it the largest supplied application category. Basal insulin is essential for maintaining background glucose control and is widely used among people with type 1 diabetes and adults with advanced type 2 diabetes. The category is undergoing significant innovation as manufacturers move beyond once-daily administration. During 2026, once-weekly basal insulin entered the U.S. market, reducing administration from 7 injections each week to 1. This development creates a new competitive dimension around treatment convenience and adherence. Long Acting insulin also benefits from extensive pen-based administration and compatibility with modern glucose-monitoring technologies. Continued development of prolonged-duration analogues is expected to support the category's leading position throughout the forecast period.

Pre-Mix Insulin: Pre-Mix Insulin is estimated to represent approximately 11.2% of application demand in 2026. These formulations combine insulin components with different action profiles and can simplify treatment by reducing the need to manage multiple separate products. Pre-Mix Insulin remains particularly relevant in Asia-Pacific and other markets where structured twice-daily or similar administration schedules are commonly used. The category can offer practical advantages for patients who prefer standardized treatment routines, although it provides less dosing flexibility than individualized basal-bolus therapy. Expanding outpatient diabetes services and pen-based administration are supporting continued use across developing healthcare systems. Through 2035, Pre-Mix Insulin is expected to retain a meaningful share, especially among patients requiring simplified treatment schedules and healthcare systems emphasizing practical administration.

Download FREE Sample to learn more about this report.

Regional Outlook

North America:

North America is estimated to account for approximately 39.6% of insulin demand in 2026, making it the largest regional market. The region benefits from extensive diabetes screening, strong insurance coverage, high utilization of Insulin Analogue and widespread adoption of prefilled pens and continuous glucose monitoring. The United States represents the majority of regional consumption and has approximately 38 million adults living with diabetes. Healthcare providers increasingly use individualized treatment strategies incorporating basal and mealtime insulin alongside digital glucose-management technologies. The market also supports rapid commercialization of advanced pharmaceutical products, making North America strategically important for manufacturers developing new insulin formulations.

The region entered an important innovation cycle in 2026 with the introduction of once-weekly basal insulin. The first U.S. approval occurred in March 2026, followed by another weekly basal formulation in September 2026. These therapies reduce basal administration from around 365 injections per year to approximately 52. Biosimilar competition is also increasing after the first rapid-acting insulin biosimilar received approval in February 2025. These changes are encouraging established manufacturers to compete more aggressively through convenience, manufacturing reliability and delivery-system innovation. North America is expected to remain a leading market through 2035 because of its combination of large treated populations, advanced clinical infrastructure and early adoption of new therapeutic technologies.

Europe:

Europe is estimated to represent approximately 25.4% of global insulin demand in 2026. The region has well-established public healthcare systems, broad diabetes-screening programs and substantial use of insulin pens and analogue products. Several European healthcare markets adopted advanced basal insulin technologies ahead of wider international commercialization, supporting strong physician familiarity with innovative formulations. Population aging and growing type 2 diabetes prevalence are reinforcing long-term insulin demand, while healthcare systems continue to emphasize effective glucose management to reduce expensive complications. Insulin Analogue represents the largest product category in much of Western and Northern Europe, while Regular Human Insulin continues to maintain a role in selected procurement programs.

European insulin demand is increasingly influenced by cost-effectiveness assessment and biosimilar adoption. Public healthcare systems evaluate new products against established therapies, creating strong pressure on manufacturers to demonstrate measurable convenience or clinical advantages. Once-weekly basal insulin provides a notable example because it reduces administration from 7 injections each week to 1. Digital diabetes-management systems are also becoming increasingly integrated into routine care, with continuous glucose-monitoring technology allowing more detailed assessment of insulin response. Through 2035, Europe is expected to maintain a significant position in advanced insulin adoption while simultaneously supporting biosimilar competition and cost-conscious procurement.

Asia-Pacific:

Asia-Pacific is estimated to account for approximately 28.7% of insulin demand in 2026 and is positioned to record the strongest long-term volume expansion. The region includes very large populations with diabetes and substantial numbers of patients who remain undiagnosed or inadequately treated. Adult diabetes prevalence has reached approximately 20% in parts of the wider South-East Asian disease environment, indicating considerable long-term treatment requirements. Expanding urbanization, improved health insurance, greater screening and increasing specialist capacity are bringing additional patients into structured diabetes-management programs. Rising utilization of insulin pens is also improving administration convenience among urban populations.

The region has a growing domestic manufacturing base, particularly in China, where Tonghua Dongbao, Ganlee, United Laboratory and Jiangsu Wanbang participate in insulin production and competition. This regional manufacturing capacity supports lower-cost supply while increasing competitive pressure on multinational suppliers. Regular Human Insulin remains significant across public and affordability-focused channels, while Insulin Analogue is expanding as healthcare spending and reimbursement improve. Asia-Pacific therefore offers opportunities across both established and advanced formulations. Through 2035, the region is expected to become increasingly influential in biosimilar development, biologics manufacturing and high-volume insulin procurement.

Latin America:

Latin America is estimated to account for approximately 3.4% of global insulin demand in 2026. Brazil, Mexico, Argentina and other major markets are experiencing increasing diabetes prevalence and greater demand for long-term glucose management. Public healthcare procurement plays a central role because large patient populations depend on government-funded medicine programs. Insulin manufacturers consequently compete on product availability, distribution reliability and affordability as well as formulation performance. Pen-based administration is becoming more common in major urban areas, while vials continue to retain relevance in cost-sensitive healthcare settings.

Growth through 2035 is expected to be supported by expanding diagnosis, greater primary-care screening and wider availability of biosimilar insulin. Regular Human Insulin continues to serve affordability-focused programs, while Insulin Analogue adoption is increasing among insured and urban populations. The ability to maintain reliable cold-chain distribution across geographically extensive markets represents an important competitive requirement. Manufacturers capable of combining competitive pricing with dependable logistics and multiple insulin formulations are expected to strengthen their presence as national diabetes-management programs expand.

Middle East & Africa:

Middle East & Africa is estimated to represent approximately 2.9% of global insulin demand in 2026. The region contains sharply different healthcare environments, ranging from advanced treatment systems in Gulf countries to areas with limited access to insulin and glucose monitoring. Adult diabetes prevalence is approximately 20% across parts of the Eastern Mediterranean disease environment, highlighting substantial long-term treatment requirements. Wealthier markets increasingly use Insulin Analogue, advanced pens and digital glucose-monitoring systems, while affordability and medicine availability remain central issues across lower-income countries.

A major regional opportunity lies in improving treatment coverage through public procurement, distribution investment and broader access to cost-efficient insulin. International diabetes objectives call for affordable insulin and blood-glucose self-monitoring access for 100% of people with type 1 diabetes by 2030, providing a clear target for healthcare-system improvement. Regular Human Insulin is expected to remain important because of affordability considerations, while Insulin Analogue adoption should gradually increase among urban and insured patients. Companies with strong temperature-controlled distribution networks and reliable supply capacity are expected to hold an advantage as diabetes-care infrastructure develops.

List of Top Insulin Companies

• Novo Nordisk
• Sanofi-Aventis
• Eli Lilly
• Tonghua Dongbao
• Ganlee
• United Laboratory
• Jiangsu Wanbang

Top 2 Companies Market Share

Novo Nordisk: Novo Nordisk is estimated to account for approximately 35.2% of the insulin competitive landscape in 2026, supported by a broad portfolio of basal and mealtime insulin formulations and extensive international distribution. The company's competitive position strengthened further in March 2026 when its once-weekly basal insulin received U.S. approval for adults with type 2 diabetes. The formulation provides 7 days of basal activity from a single injection, reducing administration from 7 injections per week to 1. Its development program involved several thousand adults across multiple Phase 3 trials, illustrating the company's investment in longer-duration insulin technology.

Eli Lilly: Eli Lilly is estimated to represent approximately 24.1% of the competitive insulin landscape in 2026. The company maintains a longstanding position in diabetes treatment and continues to invest in next-generation insulin technology and manufacturing. Its once-weekly basal insulin received U.S. approval in September 2026 following Phase 3 studies involving more than 3,400 adults with type 2 diabetes. The therapy can reduce annual basal injections by more than 300 compared with once-daily treatment. This development strengthens the company's participation in the emerging weekly basal category and demonstrates how competition among major insulin manufacturers is shifting toward reduced administration frequency and greater patient convenience.

Investment Analysis

Investment across the insulin industry is increasingly focused on biologics manufacturing, aseptic filling capacity, advanced delivery devices and longer-duration formulations. New insulin production requires specialized fermentation, purification and sterile packaging systems capable of maintaining highly consistent quality across millions of doses. Manufacturers are therefore expanding facilities that can support cartridges, prefilled pens and other injectable presentations. Large pharmaceutical companies have announced multibillion-dollar manufacturing programs in recent years to strengthen injectable medicine capacity, while regional producers continue to invest in recombinant insulin and biosimilar production. The increasing diabetes population of approximately 830 million people creates a significant requirement for scalable supply infrastructure. Investment strategies are therefore balancing sophisticated product innovation with high-volume manufacturing efficiency.

Emerging economies represent another important investment area because approximately 450 million adults with diabetes remained untreated in 2022, with around 90% of these untreated individuals located in low- and middle-income countries. Local manufacturing, regional packaging, public procurement partnerships and cold-chain logistics can improve access while reducing reliance on imported finished products. Asia-Pacific is particularly attractive because domestic manufacturers are building expertise in recombinant and analogue insulin. Investment is also increasing in biosimilar development as healthcare systems seek broader treatment choice. Companies capable of operating across 2 strategic areas, advanced analogue innovation and cost-efficient large-scale manufacturing, are expected to be better positioned as global healthcare systems attempt to expand treatment coverage through 2035.

New Product Development

New product development is increasingly concentrated on reducing injection frequency and improving treatment convenience. Once-weekly basal insulin became a major commercial development in 2026, providing 7 days of basal insulin activity from a single administration. This reduces the approximate annual injection burden from 365 injections with once-daily basal treatment to around 52. The technology has progressed through large Phase 3 programs involving thousands of adults with type 2 diabetes, demonstrating substantial industry commitment to longer-duration insulin. Manufacturers are also optimizing high-concentration formulations, injection devices and titration strategies to ensure that extended-duration products remain practical for routine clinical use. These developments indicate that convenience and adherence are becoming increasingly important alongside glycemic effectiveness.

Biosimilar development represents a second major product-development pathway. The first U.S. rapid-acting insulin biosimilar received approval in February 2025 and was authorized in 2 administration formats. This development extended biosimilar competition into an application category historically dominated by established branded analogues. Future product pipelines are expected to include additional Rapid Acting and Long Acting biosimilars, advanced pens and digitally supported insulin administration. Connected delivery devices can capture injection timing and dose information, while continuous glucose monitoring can provide detailed feedback regarding treatment response. Through 2035, insulin development is expected to progress simultaneously toward longer duration, easier administration and broader affordability.

Five Recent Developments

• September 2026: Eli Lilly received U.S. approval for its once-weekly basal insulin for adults with type 2 diabetes after a Phase 3 clinical program involving more than 3,400 participants, reducing basal administration to 1 injection every 7 days.
• March 2026: Novo Nordisk received U.S. approval for a once-weekly basal insulin for adults with type 2 diabetes, introducing an option that reduces conventional basal dosing from 7 injections each week to a single weekly administration.
• February 2025: The first rapid-acting insulin biosimilar was approved in the United States for adults and pediatric patients with diabetes, with 2 delivery presentations consisting of a 3 mL prefilled pen and 10 mL multidose vial.
• December 2024: Eli Lilly announced a major expansion of injectable medicine manufacturing capacity in the United States involving approximately USD 3 billion of additional investment and plans for around 750 additional skilled manufacturing positions.
• March 2024: Once-weekly insulin icodec advanced through European regulatory review following a Phase 3 development program involving several thousand participants, supporting commercial introduction of basal therapy designed to provide approximately 7 days of coverage.

Report Coverage

The Insulin Market report evaluates industry conditions across the 2026-2035 forecast period and examines 3 supplied product types comprising Animal Insulin, Regular Human Insulin and Insulin Analogue. Application coverage includes 5 categories consisting of Rapid Acting, Short Acting, Intermediate Acting, Long Acting and Pre-Mix Insulin. The analysis evaluates changing diabetes prevalence, insulin accessibility, prescribing behavior, biosimilar competition, longer-duration formulation development, insulin-pen adoption and manufacturing requirements. Regional assessment includes North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. North America is estimated to hold approximately 39.6% of market demand in 2026, while Asia-Pacific represents approximately 28.7% and continues to demonstrate substantial long-term volume potential.

The report also examines the competitive activities of 7 supplied companies comprising Novo Nordisk, Sanofi-Aventis, Eli Lilly, Tonghua Dongbao, Ganlee, United Laboratory and Jiangsu Wanbang. Coverage includes recent product development, manufacturing investment, biosimilar activity, regional expansion and changing delivery technologies. Particular attention is placed on once-weekly basal insulin, which reduces administration from approximately 365 injections annually to around 52, and on the growing role of insulin biosimilars in established Rapid Acting and Long Acting categories. The analysis further considers the approximately 830 million people living with diabetes globally, the approximately 450 million untreated adults identified in 2022 and international objectives designed to expand insulin access by 2030. These indicators provide a structured view of the demand, innovation and accessibility factors expected to shape the insulin industry through 2035.